Mountain View Pharmaceuticals
Private Company
Funding information not available
Overview
Mountain View Pharmaceuticals is a private, clinical-stage biotech focused on applying advanced PEGylation chemistry to create improved therapeutics for rare and metabolic diseases. The company's core intellectual property is its 'Better PEGs' platform, designed to optimize drug delivery. While specific pipeline details are not fully public, its lead asset is PEG 40-Uricase, indicating a focus on conditions like refractory gout. The company operates through partnerships and appears to be in a pre-revenue or early development stage.
Technology Platform
Proprietary 'Better PEGs' platform involving novel polyethylene glycol (PEG) polymers and conjugation chemistries designed to optimize the pharmacokinetics, safety, and efficacy of biologic drugs.
Opportunities
Risk Factors
Competitive Landscape
MVP competes directly with other companies developing PEGylated therapeutics, notably Horizon Therapeutics (now part of Amgen) with its approved pegloticase. It also competes broadly in the advanced drug delivery technology sector, where numerous firms are developing alternative conjugation and formulation strategies to improve biologics.